periparative risk, overall morbidity and mortality is not reduced and may be increased.2

The perioperative period can be viewed as a stress test, subjecting the body to neuroendocrine, hemodynamic, thermal, and coagulation changes. These stresses are thought to account for most perioperative myocardial infarctions.3,4 Yet, we have invested relatively little effort and resources in postoperative research and management strategies. Therefore, we believe that the potential for novel discoveries and cost-effective therapies may be comparatively greater. One possible approach would be to use continuous 12-lead electrocardiographic monitoring in at-risk patients during the first 48 h after surgery. Systems are available with central alarm capabilities that can be used on a general surgical floor. Based on recent data showing that ischemia precedes postoperative cardiac events in most patients5-9 and that there is an apparent threshold of 120 min of postoperative ischemia before development of major morbidity events,10 prompt ischemia detection should allow for timely intervention and a reduced incidence of postoperative infarction. Because postoperative ischemia also predicts long-term cardiac morbidity and mortality,11 improved methods for ischemia detection could use the physiologic stress of the perioperative period as a "surgical stress test."

In summary, if we wish to reduce perioperative cardiac complications, we need to develop a comprehensive approach that deploys our resources throughout the perioperative period most effectively. We contend that systematic study and consideration to the relatively unexplored avenues of postoperative management should be made before we make additional and massive investments in approaches that have been in place for decades.

Brian A. Rosenfeld, M.D., F.C.C.M.
Associate Professor
Anesthesiology
Medicine and Surgery
Michael J. Breslow, M.D., F.C.C.M.
Associate Professor
Anesthesiology
Medicine and Surgery

References
1. Manganaro, DT. Preoperative risk assessment: Many studies, few solutions. Anesthesiology 1995; 83:897-901

(Accepted for publication February 15, 1996.)

Todd Dorman, M.D.
Assistant Professor
Anesthesiology and Surgery
Adult Critical Care Division
Anesthesiology and Critical Care Medicine
Johns Hopkins
600 North Wolfe Street, Meyer 299A
Baltimore, Maryland 21287-7294

Anesthesiology
V 84, No 5, May 1996

In Reply—I generally agree with the comments of Rosenfeld et al and appreciate their clinical efforts to reduce adverse outcome for an integrative paradigm. They raise a number of specific issues that should be addressed.

There is no question that the development of a paradigm for cost-effective preoperative assessment of high-risk patients undergoing surgery is challenging. No one test can comprehensively model the myriad pathophysiologic changes that can lead to myocardial infarction. Therefore, an optimal paradigm must consider both the chronic and acute disease states of the patient, as well as the anticipated pathophysiologic changes that occur intraoperatively and postoperatively. Development of such a paradigm is possible using large-scale outcome studies that incorporate these physiologic and clinical factors to assess available technologies and routine and specialized testing for both efficacy and cost-effectiveness. However, Rosenfeld et al question even the need for a paradigm. The solution of the problem of perioperative cardiac morbidity requires the development of perioperative monitoring and therapeutic techniques. However, without an appropriate preoperative paradigm, we cannot hope to develop comprehensive and cost-effective solutions for the following reasons:

First, the use of intensive monitoring and aggressive therapy for all 9 million patients at risk in the United States annually (with an additional 9 million throughout the world) is not a practical goal,
CORRESPONDENCE

the cost incurred would be substantial. Even if the cost per patient of such additional monitoring and therapy were only $500 per day (probably an underestimate), the resultant expense would be $18 billion annually worldwide. Given that such monitoring and therapy may reduce perioperative cardiac morbidity by 50% (probably an overestimate) and that the health-care expenditure associated with perioperative cardiac morbidity is approximately $40 billion annually, at least $18 billion would be expended to save, at most, $20 billion. Perhaps a better approach would be to apply preoperative assessment strategies to identify those patients of the 18 million at highest risk for perioperative ischemia, who, once identified, would become the appropriate subset for intensive monitoring and aggressive therapy. For example, Hollenberg et al. have identified five clinical factors that predict patients at highest risk for perioperative ischemia: left ventricular hypertrophy by electrocardiogram, history of hypertension, diabetes mellitus, definite coronary artery disease, and use of digitalis that is, the presence of four or five of these factors is associated with a 77% risk of postoperative ischemia. Given that approximately 10% of the 18 million patients at risk belong to the group at highest risk for perioperative ischemia, applying the Hollenberg risk stratification paradigm will reduce the expenditure by 90%, from $18 billion to $2 billion, which appears to be cost-effective. Additionally, for certain subsets of patients, specialized testing may refine the risk subsets, as has been suggested by Eagle et al. and others.2,4 Accordingly, preoperative stratification is not only useful but also necessary for the development of cost-effective approaches to managing a candidate population of 18 million patients per year.

Second, preoperative assessment may allow identification of patients who will benefit from angioplasty or coronary artery bypass surgery. Although several studies have concluded that mechanical revascularization may not reduce future risk (as suggested by Rosenberg and colleagues), most studies suggest that successful revascularization reduces perioperative risk for subsequent noncardiac surgery.1,2,4

Third, there is no question that false-negative findings are a limitation of virtually all preoperative testing procedures. The occurrence of predictors usually is far greater than the occurrence of outcomes, resulting in universally low positive predictive values for nonroutine specialized testing. All predictors or screening tests have similar positive predictive limitations. For example, angiography is a predictor of myocardial infarction; however, of the 5 million patients in the United States who experience angina annually, only 1.5 million have a myocardial infarction. This does not mean that perioperative predictors or screening tests are not useful; rather, high-risk subsets of patients likely to benefit from such testing must be identified to develop cost-effective strategies.

In conclusion, the development of the optimal preoperative paradigm is difficult but necessary to delineate the highest-risk patient subsets, thereby providing the essential milieu for designing cost-effective diagnostic and therapeutic approaches.

Dennis T. Mangan, Ph.D., M.D.
Professor of Anesthesia
University of California, San Francisco
Anesthesiology Service
150 Clement Street
San Francisco, California 94121
Director, McSPI Research Group

References

(Accepted for publication February 15, 1996.)

Anesthesiology, V 84, No 5, May 1996

REVIEW

James C. Eisenac

The Pharmacology of T. Andrew Bowditch

Much of anesthesiology and its basic science field is a lack of good textbook, the Pharmacology will be in adequate depth, regardless of anesthesiologists, and clinical as to fill that gap and cover the pharmacology of the specialty of anesthesiology.

The organization of this new book is from an introductory text to a comprehensive one. It contains numerous general topics, such as one on pharmacology and applies to the book, despite the drug and “applied” sections, primarily clinical concepts among the various pharmacokinetics are covered in detail in this book. The basic concepts of adrenergic agents are

Coverage is thorough in all aspects of clinical perspective, including excellent content (excluding epidural and local anesthesia), local anesthesia, and the exception of ketamine and the neuromuscular blockers. Two final sections cover the topic by topic, including anecdotals and adjuvants, and nonsteroidal anti-inflammatory drugs. Interestingly, there is an extensive section on the surgery and delivery of pharmacokinetics. A chapter on antiinflammatory agents, therapy, and its chapter is on depression in this section. Overall, most drugs in children are discussed in the pharmacology for children (or intravenous drugs).